Evaluation of Serums levels of Glucose, Lipids and Lipoproteins after Induced 3, 4 Methylenedioxymeth Amphetamine (MDMA, Ecstasy) in dog

Subject Areas : Journal of Large Animal Clinical Science Research(JLACSR)

Received: 2021-07-06 Accepted : 2021-07-06 Published : 2008-12-21

Keywords: Cholesterol, glucose, Ecstasy, Triglyceride, Dog, Lipoproteins,

Abstract :

In order to evaluate the effect of Ecstasy on glucose, lipids andlipoproteins metabolism, Five 3.5 - 4 years old male mixed breed dogs wereselected. Blood samples were collected and recorded as time zero or controlsampels before drug administration. Then, each dog was given Ecstasy tablesorally at a single dose (150 mg/kg). Blood samples were collected from thecephalic vein at time intervals of 30 minutes, 1, 2, 4, 8, 24, 48 hoursand 7 and 20 days following administration. Serum levels of Glucose,Triglyceride, Cholesterol, HDL, LDL and VLDL were measured bycolorimetric method using spectrophotometer and commercial diagnostickits (ziest chem). The results of this study showed significant increase inserumic levels of Glucose, Cholesterol and LDL, and Triglyceride VLDL up < br />to 24 hours following drug adminstration that could be due to the effect ofdrug on liver and body metabolism(p < 0.05). But Serum levels of HDL wasnot significant (p>0.05) after this time. Therefore, using MDMA even for theshort time and single dose could be affected on normal function of liver andcould change metabolism of lipids and lipoproteins.

References:

1-     اطیابی،ن (1384): کلینیکال پاتولوژی دامپزشکی، انتشارات دانشگاه تهران، چاپ اول، جلد اول، صفحات 201 -245.

2-     مجابی، ع(1384): بیوشیمی درمانگاهی دامپزشکی، انتشارات نوربخش، صفحات 39- 162.

3-     مفیدی، آ (1385): اکستازی چیست؟،

WWW.Prisons.ir

4-     نظیفی، س(1380): علوم آزمایشگاهی دامپزشکی (آسیب شناسی بالینی)، انتشارات دانشگاه شیراز، صفحات 243-441.

5-      Beitia G, Cobreros A, Sainz L, Cenarruzabeita E.,(2000): Ecstasy- induced toxicity in rat liver.Liver international. 20, 10: 1-8.

6-      Delaforge M, Jaouen M, Bouille G.,(1999) :Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D  Environ Toxicol Pharmacol. 7:153-158.

7-      Frith C.H, Chang L.W, Lattin D.L, walls R.C, Hamm J, Doblin R.,(2004): Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat. Fundamental and Applied Toxicology, 9, 1:110-119.

8-      Green A.R, Mechan A.O, Ellott M, O'shea E, ColandoI., (2003): The pharmacology and clinical pharmacology of 3,4-Methlenedioxymethamphetanine (MDMA, "Ecstasy"). Pharmacol Rev  55: 463-508.

9-      Hall A.P, Henry J.A., (2006): acute toxic effects of ' Esctasy' (MDMA) and related compounds: overview of pathophysiology and clinical managemtn. Brithish Journal of Anaesthesia.96,6: 678-85.

10-  Kalant H., (2001): The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMA J.165,7: 917-28.

Mas M, Farre M, de la Tore R, Roset P.N, Ortuo J, Segura J.,(1999): Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-ethylenedioxymethamphetamine in humans. J Pharmacol  Exp Ther. 290:136-45.